Back to Search Start Over

Disseminated Tuberculosis With an Atypical Cutaneous Manifestation in a Hematopoietic Cell Transplant Patient in the Early Posttransplant Period: Case Report and Review of the Literature.

Authors :
Czech MM
Dioverti MV
Karaba AH
Jain T
Talluru SM
Sunshine JC
Kang J
Parrish N
Kates OS
Source :
Open forum infectious diseases [Open Forum Infect Dis] 2022 Nov 29; Vol. 9 (12), pp. ofac643. Date of Electronic Publication: 2022 Nov 29 (Print Publication: 2022).
Publication Year :
2022

Abstract

We describe an unusual case of posttransplant tuberculosis reactivation in a man who underwent allogeneic hematopoietic cell transplant. Concomitant with disseminated adenovirus infection, reactivation of tuberculosis manifested as disseminated, nonfollicular pustules on day +49. Skin biopsy was obtained on day +50. Initial histopathologic evaluation did not suggest mycobacterial infection, but tissue stain showed acid-fast organisms, which were subsequently identified as Mycobacterium tuberculosis . Shortly after the cutaneous presentation of tuberculosis, the patient died on day +52. Our case is among a paucity of reports describing tuberculosis reactivation in hematopoietic cell transplant patients in the early posttransplant period. It highlights the difficulty of diagnosing contemporaneous systemic infections, and it presents a rare and atypical cutaneous manifestation of tuberculosis in a hematopoietic cell transplant patient. Our case and review of the literature emphasize the need for further research to elucidate risk factors associated with early posttransplant reactivation of tuberculosis, and the importance of remaining vigilant for active tuberculosis in hematopoietic cell transplant patients with epidemiologic risk factors.<br />Competing Interests: Potential conflicts of interest. AHK reports receiving consulting fees from Roche. TJ reports institutional research support from CTI Biopharma, Syneos Health, Incyte; Consultancy with Targeted Healthcare Communications; and advisory board participation with Care Dx, Bristol Myers Squibb, Incyte, Abbvie, and CTI.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Details

Language :
English
ISSN :
2328-8957
Volume :
9
Issue :
12
Database :
MEDLINE
Journal :
Open forum infectious diseases
Publication Type :
Report
Accession number :
36570971
Full Text :
https://doi.org/10.1093/ofid/ofac643